|
Tovorafenib Clinical Trials
4 actively recruiting trials across 3 locations
No change since May 2026
Also known as: AMG-2112819, BIIB 024, BIIB-024, BIIB024, BSK1369 +13 more
Pipeline
Phase 1: 1Phase 2: 2Phase 1/2: 1
Top Sponsors
- Sabine Mueller, MD, PhD1
- National Cancer Institute (NCI)1
- Ipsen1
- Day One Biopharmaceuticals, Inc.1
Indications
- Cancer4
- Low-grade Glioma2
- Recurrent Craniopharyngioma1
- Craniopharyngioma, Child1
- Refractory Hairy Cell Leukemia1
Other1 trial
Birmingham, Alabama1 trial
Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
University of Alabama at Birmingham
Phase 2
San Francisco, California1 trial
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
UCSF Benioff Children's Hospital
Phase 2
Bethesda, Maryland1 trial
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
NCI - Center for Cancer Research
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.